New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:04 EDTLGNDLigand says LGD-6972 well-tolerated in Phase 1 study
Ligand Pharmaceuticals announced data from a Phase 1 clinical trial with LGD-6972 that demonstrate favorable safety, tolerability and pharmacokinetics in normal healthy volunteers and in subjects with type 2 diabetes mellitus, and also demonstrate a robust response on fasting plasma glucose after a single dose. LGD-6972 is Ligandís novel glucagon receptor antagonist and these first-in-human data were presented at the American Diabetes Associationís 74th Scientific Sessions meeting underway in San Francisco. Highlights of the single-ascending dose trial involving a total of 56 subjects include: LGD-6972 was well-tolerated; there were no clinically significant or dose-dependent changes in hematology, clinical chemistry, urinalysis, ECG or vital signs, and no serious adverse events. LGD-6972 was well-absorbed after oral administration; peak plasma concentrations were reached approximately 5 to 8 hours post dose with a long elimination half-life of approximately 50 hours, supporting once-daily dosing. After a single dose, LGD-6972 reduced fasting plasma glucose in normal healthy volunteers and in subjects with type 2 diabetes. Fasting plasma glucose was reduced by 57 mg/dL in subjects with type 2 diabetes, suggesting a robust response in this acute study.
News For LGND From The Last 14 Days
Check below for free stories on LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 15, 2014
09:31 EDTLGNDLigand, Avion Pharmaceuticals sign Captisol license agreement
Subscribe for More Information
August 14, 2014
08:12 EDTLGNDLigand signs multi-program Captisol license agreement with Avion Pharmaceuticals
Subscribe for More Information
August 12, 2014
07:44 EDTLGNDMarinus Pharmaceuticals enters into agreement with CyDex Pharmaceuticals
Marinus Pharmaceuticals (MRNS) announced that it has entered into an agreement with CyDex Pharmaceuticals, a wholly owned subsidiary of Ligand Pharmaceutical (LGND), for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous dose form of ganaxolone with Captisol.
August 11, 2014
16:11 EDTLGNDLigand announces $200M share repurchase plan
Subscribe for More Information
16:11 EDTLGNDLigand files to sell $225M of convertible senior notes due 2019
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use